New pill targets genetic driver in advanced cancers
NCT ID NCT07407504
Summary
This early-stage study is testing a new oral drug, GenSci145, in people with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it might help control the cancer. It will be tested alone and in combination with other cancer drugs, primarily in people with advanced breast cancer who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH PIK3CA-MUTATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Cancer Hospital of the Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.